Literature DB >> 32633830

Sarcopenia Definition & Outcomes Consortium Defined Low Grip Strength in Two Cross-Sectional, Population-Based Cohorts.

Sheena M Patel1, Kate A Duchowny1,2, Douglas P Kiel3, Rosaly Correa-de-Araujo4, Roger A Fielding5, Thomas Travison3, Jay Magaziner6, Todd Manini7, Qian-Li Xue8, Anne B Newman9, Karol M Pencina10, Adam J Santanasto9, Shalender Bhasin10, Peggy M Cawthon1,2.   

Abstract

BACKGROUND/
OBJECTIVES: The extent to which the prevalence of muscle weakness in the US population varies by different putative grip strength constructs developed by the Sarcopenia Definitions and Outcomes Consortium (SDOC) has not been described.
DESIGN: Cross-sectional analysis.
SETTING: Two nationally representative cohorts-2010 and 2012 waves of the Health and Retirement Survey and round 1 (2011) of the National Health and Aging Trends Survey. PARTICIPANTS: Adults aged 65 years and older (n = 12,984) were included in these analyses. MEASUREMENTS: We analyzed three constructs of muscle weakness developed by the SDOC, and found to be associated with mobility disability for men and women, respectively: absolute grip strength (<35.5 kg and 20 kg); grip strength standardized to body mass index (<1.05 kg/kg/m² and 0.79 kg/kg/m²); and grip strength standardized to weight (<0.45 kg/kg and 0.337 kg/kg). We estimated the prevalence of muscle weakness defined by each of these constructs in the overall older US population, and by age, sex, race, and ethnicity. We also estimated the sensitivity and specificity of each of the grip strength constructs to discriminate slowness (gait speed <0.8 m/s) in these samples.
RESULTS: The prevalence of muscle weakness ranged from 23% to 61% for men and from 30% to 66% for women, depending on the construct used. There was substantial variation in the prevalence of muscle weakness by race and ethnicity. The sensitivity and specificity of these measures for discriminating slowness varied widely, ranging from 0.30 to 0.92 (sensitivity) and from 0.17 to 0.88 (specificity).
CONCLUSIONS: The prevalence of muscle weakness, defined by the putative SDOC grip strength constructs, depends on the construct of weakness used. J Am Geriatr Soc 68:1438-1444, 2020.
© 2020 The American Geriatrics Society.

Entities:  

Keywords:  gait; muscle; physical performance; sarcopenia

Mesh:

Year:  2020        PMID: 32633830     DOI: 10.1111/jgs.16419

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  10 in total

1.  Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement.

Authors:  Lorenzo M Donini; Luca Busetto; Stephan C Bischoff; Tommy Cederholm; Maria D Ballesteros-Pomar; John A Batsis; Juergen M Bauer; Yves Boirie; Alfonso J Cruz-Jentoft; Dror Dicker; Stefano Frara; Gema Frühbeck; Laurence Genton; Yftach Gepner; Andrea Giustina; Maria Cristina Gonzalez; Ho-Seong Han; Steven B Heymsfield; Takashi Higashiguchi; Alessandro Laviano; Andrea Lenzi; Ibolya Nyulasi; Edda Parrinello; Eleonora Poggiogalle; Carla M Prado; Javier Salvador; Yves Rolland; Ferruccio Santini; Mireille J Serlie; Hanping Shi; Cornel C Sieber; Mario Siervo; Roberto Vettor; Dennis T Villareal; Dorothee Volkert; Jianchun Yu; Mauro Zamboni; Rocco Barazzoni
Journal:  Obes Facts       Date:  2022-02-23       Impact factor: 4.807

2.  Associations of handgrip strength with morbidity and all-cause mortality of cardiometabolic multimorbidity.

Authors:  Yanqiang Lu; Guochen Li; Pietro Ferrari; Heinz Freisling; Yanan Qiao; Luying Wu; Liping Shao; Chaofu Ke
Journal:  BMC Med       Date:  2022-06-03       Impact factor: 11.150

3.  Barriers to eating are associated with poor physical function in older women.

Authors:  Marian L Neuhouser; Rebecca P Hunt; Linda Van Horn; James M Shikany; Marcia L Stefanick; Karen C Johnson; Robert Brunner; Brad Cannell; Irene E Hatsu; Lesley F Tinker
Journal:  Prev Med       Date:  2020-08-12       Impact factor: 4.018

4.  Application of Cut-Points for Low Muscle Strength and Lean Mass in Mobility-Limited Older Adults.

Authors:  Gregory J Grosicki; Thomas G Travison; Hao Zhu; Jay Magaziner; Ellen F Binder; Marco Pahor; Rosaly Correa-de-Araujo; Peggy M Cawthon; Shalender Bhasin; Denise Orwig; Susan Greenspan; Todd Manini; Joe Massaro; Adam Santanasto; Sheena Patel; Roger A Fielding
Journal:  J Am Geriatr Soc       Date:  2020-07-07       Impact factor: 5.562

5.  Motor function is the primary driver of the associations of sarcopenia and physical frailty with adverse health outcomes in community-dwelling older adults.

Authors:  Aron S Buchman; Sue E Leurgans; Tianhao Wang; Michal Schnaider-Beeri; Puja Agarwal; Robert J Dawe; Osvaldo Delbono; David A Bennett
Journal:  PLoS One       Date:  2021-02-02       Impact factor: 3.240

6.  Mixed Neuropathologies, Neural Motor Resilience and Target Discovery for Therapies of Late-Life Motor Impairment.

Authors:  Aron S Buchman; David A Bennett
Journal:  Front Hum Neurosci       Date:  2022-03-24       Impact factor: 3.169

7.  Implications of Race and Ethnicity in Sarcopenia US National Prevalence of Sarcopenia by Muscle Mass, Strength, and Function Indices.

Authors:  Bigman G; Ryan As
Journal:  Gerontol Geriatr Res       Date:  2021-04-16

Review 8.  Muscle Wasting and Sarcopenia in Heart Failure-The Current State of Science.

Authors:  Alessia Lena; Markus S Anker; Jochen Springer
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

9.  Performance of the EWGSOP2 Cut-Points of Low Grip Strength for Identifying Sarcopenia and Frailty Phenotype: A Cross-Sectional Study in Older Inpatients.

Authors:  Anna K Stuck; Nina C Mäder; Dominic Bertschi; Andreas Limacher; Reto W Kressig
Journal:  Int J Environ Res Public Health       Date:  2021-03-28       Impact factor: 3.390

10.  Role of handgrip strength in predicting new-onset diabetes: findings from the survey of health, ageing and retirement in Europe.

Authors:  Guochen Li; Yanan Qiao; Yanqiang Lu; Siyuan Liu; Yi Ding; Xing Chen; Chaofu Ke
Journal:  BMC Geriatr       Date:  2021-07-29       Impact factor: 3.921

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.